PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay

Yasunari Sakamoto, Seri Yamagishi, Yoshinori Tanizawa, Masaomi Tajimi, Takuji Okusaka, Hidenori Ojima

研究成果: Article

5 引用 (Scopus)

抜粋

Biliary tract carcinoma (BTC) is an extremely malignant tumor, but available treatment options are limited. Despite of needs for novel therapies, few BTC-related resources are currently available for evaluation of candidate drugs. To address this issue, we have recently established 13 cell lines from surgical specimens from Japanese BTC patients. In the present study, we evaluated four new molecular targeting agents using our BTC cell-based assay panel with 17 BTC cell lines. PI3K/ mTOR dual inhibitor LY3023414 showed activity at submicromolar concentration ranges against 13 of the 17 cell lines tested, including the ones with gemcitabine insensitivity. In conclusion, we demonstrated that in vitro study with the BTC cell line panel would be an efficient approach to screen for novel therapeutic strategies. Although this is preliminary result and further investigations are required for confirmation, PI3K/mTOR inhibitor might be a potential target for BTC drug development.

元の言語English
ページ(範囲)396-399
ページ数4
ジャーナルJapanese Journal of Clinical Oncology
48
発行部数4
DOI
出版物ステータスPublished - 2018 4 1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

フィンガープリント PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用